突触囊泡蛋白 SV2 是一种新型的跨膜载体
M B Feany1, S Lee, R H Edwards
1Department of Neurobiology Harvard Medical School Boston, Massachusetts 02115.
Cell
|September 4, 1992
概括
突触囊泡蛋白2 (SV2) 可能作为一种新型的载体. 它的序列表明SV2将神经递质导入突触囊泡,这是神经元通信的关键过程.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 突触囊泡对于储存和释放神经递质至关重要.
- 神经递质重新填充到突触囊泡依赖于质子梯度,但涉及到未知的分子机械.
- 了解神经递质传递器是理解突触功能的关键.
研究的目的:
- 确定负责神经递质进口到突触囊泡中的分子机制.
- 描述突触囊泡蛋白2 (SV2) 和它在神经递质运输中的潜在作用.
主要方法:
- 对突触囊泡蛋白 SV2 的序列分析.
- 对SV2域与已知的载体家族进行生物信息比较.
主要成果:
- SV2的氨基酸序列揭示了两组不同的六个跨膜域.
- N-终端域与葡萄糖载体具有同质性.
- 该C端域表现出与血神经递质载体的同质性.
结论:
- SV2被确定为一种新型的跨膜载体.
- 结构上的同质性表明SV2介导神经递质的运输到突触囊泡中.
- 这一发现为突触囊泡回收的关键步骤提供了一个分子候选.
相关概念视频
Overview of Secretory Vesicles
8.8K
Secretory vesicles, also known as dense core vesicles (DCVs), are membrane-bound vesicles that transport secretory proteins, such as hormones or neurotransmitters. Regulated secretory vesicles transport proteins from the trans-Golgi network to the exterior of the cell. Proteins present in regulated secretory vesicles are required to be rapidly exocytosed in large amounts upon a specific stimulus.
Various proteins regulate the aggregation of molecules inside the secretory vesicles. Chromogranins...
Various proteins regulate the aggregation of molecules inside the secretory vesicles. Chromogranins...
8.8K
Fusion of Secretory Vesicles with the Plasma Membrane
15.9K
Proteins and neurotransmitters in secretory vesicles can be released from a cell upon vesicle docking, priming, and fusion with the plasma membrane. Vesicles are docked and primed in preparation for the quick exocytosis of their contents in response to a stimulus. The fusion process is mainly carried out by a SNAP Receptor or SNARE complex, consisting of synaptobrevin, syntaxin-1, and SNAP-25.
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
15.9K
SNAREs and Membrane Fusion
10.4K
Once a transport vesicle has recognized its target organelle, the vesicular membrane needs to fuse with the target membrane to unload the cargo. Transmembrane proteins called SNAREs present on organelle membranes and their vesicles, mediate vesicle fusion.
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
10.4K
Vesicular Tubular Clusters
2.4K
After budding out from the ER membrane, some COPII vesicles lose their coat and fuse with one another to form larger vesicles and interconnected tubules called vesicular tubular clusters or VTCs. These clusters constitute a compartment at the ER-Golgi interface known as ERGIC (Endoplasmic Reticulum Golgi Intermediate Compartment). The ERGIC is a mobile membrane-bound cargo transport system that sorts proteins secreted from ER and delivers them to the Golgi.
With the help of motor proteins such...
With the help of motor proteins such...
2.4K
Clathrin Coated Vesicles
8.1K
Clathrin-coated vesicles use endocytosis to transport receptors and lysosomal hydrolases from the Golgi to the lysosome in the late secretory pathway. Clathrin-mediated endocytosis was the first described endocytic process, and Clathrin-coated vesicles remain one of the most well-studied transport vesicles. The molecular machinery that generates clathrin-coated vesicles comprises over 50 proteins that precisely coordinate vesicle formation. Cell surface receptors concentrated in indented sites...
8.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K


